Skip to main content
. 2019 Aug 28;10(9):654. doi: 10.3390/genes10090654

Table 1.

Summary of clinical trials for inherited retinal diseases (IRDs) using DNA therapies.

Gene/Condition Therapeutic Molecule Clinical Trial Identifier Status
Gene Augmentation
ABCA4 SAR422459 NCT01367444 Recruiting
SAR422459 NCT01736592 Enrolling by invitation
CHM AAV2-hCHM NCT02341807 Active, not recruiting
AAV2-REP1 NCT03496012 Recruiting
AAV2-REP1 NCT03507686 Recruiting
AAV2-REP1 NCT02407678 Active, not recruiting
rAAV2.REP1 NCT02671539 Active, not recruiting
rAAV2.REP1 NCT02077361 Completed
rAAV2.REP1 NCT01461213 Completed
AAV2-REP1 NCT03584165 Enrolling by invitation
AAV2-REP1 NCT02553135 Completed
CNGA3 AGTC-402 NCT02935517 Recruiting
AAV2/8-hG1.7p.coCNGA3 NCT03758404 Recruiting
rAAV.hCNGA3 NCT02610582 Active, not recruiting
CNGB3 rAAV2tYF-PR1.7-hCNGB3 NCT02599922 Recruiting
AAV2/8-hCARp.hCNGB3 NCT03001310 Recruiting
AAV-CNGB3 NCT03278873 Recruiting
MERTK rAAV2-VMD2-hMERTK NCT01482195 Recruiting
MYO7A UshStat NCT02065011 Enrolling by invitation
PDE6B AAV2/5-hPDE6B NCT03328130 Recruiting
RPE65 AAV OPTIREP NCT02946879 Recruiting
rAAV2-CBSB-hRPE65 NCT00481546 Active, not recruiting
AAV2-hRPE65v2- NCT00516477 Active, not recruiting
AAV2-hRPE65v2 NCT00999609 Active, not recruiting
AAV2-hRPE65v2 NCT01208389 Active, not recruiting
AAV2-hRPE65v2 NCT03602820 Active, not recruiting
tgAAG76 (rAAV 2/2.hRPE65p.hRPE65) NCT00643747 Completed
rAAV2-CB-hRPE65 NCT00749957 Completed
rAAV2-hRPE65 NCT00821340 Completed
rAAV2/4.hRPE65 NCT01496040 Completed
AAV RPE65 NCT02781480 Completed
RLBP1 CPK850 NCT03374657 Recruiting
RPGR AAV8-RPGR NCT03116113 Recruiting
AAV2/5-hRKp.RPGR NCT03252847 Recruiting
rAAV2tYF-GRK1-RPGR NCT03316560 Recruiting
RS1 AAV8-scRS/IRBPhRS NCT02317887 Recruiting
rAAV2tYF-CB-hRS1 NCT02416622 Active, not recruiting
Genome editing
CEP290 EDIT-101 (AGN-151587) NCT03872479 Recruiting
Optogenetics
Advanced RP RST-001 NCT02556736 Recruiting
Non-syndromic RP Retinitis Pigmentosa GS030-DP NCT03326336 Recruiting

Black and gray are just used to indicate the different sectiond and can be considered as headers. Gene or disease condition (first column), therapeutic molecule (second column), clinical trial identifier (third column) and the current status of the trial (last column) are indicated. Completed trials are highlighted in bold. Data obtained from https://clinicaltrials.gov/. RP: retinitis pigmentosa.